Europe Leukemia Therapeutics Market by disease condition (chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia, acute myeloid leukemia), by diagnosis (CT scan, biopsy, MRI), by treatments (chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant, stem cell therapy), by drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

Europe Leukemia Therapeutics Market by disease condition (chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia, acute myeloid leukemia), by diagnosis (CT scan, biopsy, MRI), by treatments (chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant, stem cell therapy), by drugs (Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat), and by Region - Industry Analysis, Size, Share, Growth, Trends, and Forecasts (2016–2021)

ID: 824 | Pages: 137 | October 2016 | Region: Europe


The Europe Leukemia Therapeutics market has been estimated at USD 1.51 Billion in 2016 and is projected to reach USD 2.26 Billion by 2021, at a CAGR of 8.4% during the forecast period from 2016 to 2021.  Leukemia is commonly caused due to the high exposure to radiations, unhealthy lifestyle, genetic factors, and environmental conditions. Leukemia cases are more common in adults and are observed to progress with aging. It can be identified by the spread of the diseases and by the type of the blood cell that is affected.

The market for Leukemia Therapeutics in Europe is propelling mainly due to factors like increased innovation and R&D in the oncology sectors and growing number of biotechnology firms. But due to factors like high cost of drugs and treatments along with large number of entry-to-market barriers, the market growth is feared to diminish.

Europe market for Leukemia Therapeutics is segmented based on disease condition, diagnosis, treatments and drugs. By disease condition, the market is further sub-segmented into chronic lymphatic leukemia, acute lymphatic leukemia, chronic myeloid leukemia and acute myeloid leukemia. By diagnosis, the market is further sub-segmented into CT scan, biopsy and MRI. By treatments, the market is further sub-segmented into chemotherapy, radiation therapy, immunotherapy, surgery, targeted therapy, bone marrow transplant and stem cell therapy. By drugs, the market is further sub-segmented into Gleevec, Sapacitabine, GA101, Vasaroxine, Tosedosat. By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in leukemia therapeutic market. Gleevec was the one of the major market growth contributors, in the drugs category.

Geographically, Europe market for Leukemia Therapeutics is segmented into U.K., France, Spain, Germany, and Italy. Europe holds the second largest share in global market. A number of factors such as growing awareness of leukemia screening programs, and government support are paving the way for companies to penetrate into European Leukemia Therapeutics market.

F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb , Eisai Co. Ltd, Biogen Idec , ERYtech Pharma , Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc. are the major players of Europe Leukemia Therapeutics market.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By Disease Condition                          

                             5.1.1 Chronic Lymphatic Leukemia         

                             5.1.2 Acute Lymphatic Leukemia             

                             5.1.3 Chronic Myeloid Leukemia             

                             5.1.4 Acute Myeloid Leukemia  

              5.2 By Diagnosis                           

                             5.2.1 CT scan    

                             5.2.2 Biopsy      

                             5.2.3 MRI          

              5.3 By Treatments                        

                             5.3.1 Chemotherapy     

                             5.3.2 Radiation therapy

                             5.3.3 Immunotherapy  

                             5.3.4 Surgery    

                             5.3.5 Targeted Therapy

                             5.3.6 Bone marrow transplant  

                             5.3.7 Stem Cell Therapy

              5.4 By Drugs                    

                             5.4.1 Gleevec    

                             5.4.2 Sapacitabine         

                             5.4.3 GA101      

                             5.4.4 Vasaroxine            

                             5.4.5 Tosedosat             

6. Geographical Analysis                                         

                             6.1 Introduction             

                             6.2 U.K 

                             6.3 Spain           

                             6.4 Germany    

                             6.5 Italy             

                             6.6 France         

7. Pipeline Product Analysis                                    

              7.1 Overview                                

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 F. Hoffmann-La Roche Ltd                 

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 GlaxoSmithKline Pharmaceuticals Limited                  

              9.3 Novartis International AG                  

              9.4 Bristol-Myers Squibb                          

              9.5 Eisai Co. Ltd              

              9.6 Biogen Idec               

              9.7 ERYtech Pharma                    

              9.8 Celgene Corporation                           

              9.9 Genmab A/S                           

              9.10 Cephalon Inc.                       

              9.11 Clavis Pharma                      

              9.12 Pfizer Inc.                

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Europe Leukemia Therapeutics Market By Region, From 2016-2021 (USD Billion)
  2. Europe Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  3. Europe Cchronic Lymphatic Leukemia Market By Region, From 2016-2021 (USD Billion)
  4. Europe Acute Lymphatic Leukemia Market By Region, From 2016-2021 (USD Billion)
  5. Europe Chronic Myeloid Leukemia Market By Region, From 2016-2021 (USD Billion)
  6. Europe Acute Myeloid Leukemia Market By Region, From 2016-2021 (USD Billion)
  7. Europe Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  8. Europe Leukemia CT scan Market By Region, From 2016-2021 (USD Billion)
  9. Europe Leukemia Biopsy Market By Region, From 2016-2021 (USD Billion)
  10. Europe Leukemia MRI Market By Region, From 2016-2021 (USD Billion)
  11. Europe Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  12. Europe Leukemia Chemotherapy Market By Region, From 2016-2021 (USD Billion)
  13. Europe Leukemia Radiation Therapy Market By Region, From 2016-2021 (USD Billion)
  14. Europe Leukemia Immunotherapy Market By Region, From 2016-2021 (USD Billion)
  15. Europe Leukemia Surgery Market By Region, From 2016-2021 (USD Billion)
  16. Europe Leukemia Targeted Therapy Market By Region, From 2016-2021 (USD Billion)
  17. Europe Leukemia Bone marrow transplant Market By Region, From 2016-2021 (USD Billion)
  18. Europe Leukemia Stem Cell Therapy Market By Region, From 2016-2021 (USD Billion)
  19. Europe Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
  20. Europe Leukemia Gleevec Market By Region, From 2016-2021 (USD Billion)
  21. Europe Leukemia Sepecitabine Market By Region, From 2016-2021 (USD Billion)
  22. Europe Leukemia GA101 Market By Region, From 2016-2021 (USD Billion)
  23. Europe Leukemia Vasaroxine Market By Region, From 2016-2021 (USD Billion)
  24. Europe Leukemia Tosedosat Market By Region, From 2016-2021 (USD Billion)
  25. U.K Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  26. U.K Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  27. U.K Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  28. U.K Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
  29. Spain Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  30. Spain Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  31. Spain Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  32. Spain Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
  33. Germany Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  34. Germany Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  35. Germany Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  36. Germany Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
  37. Italy Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  38. Italy Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  39. Italy Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  40. Italy Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
  41. France Leukemia Therapeutics Market By Disease condition, From 2016-2021 (USD Billion)
  42. France Leukemia Therapeutics Market By Diagnosis, From 2016-2021 (USD Billion)
  43. France Leukemia Therapeutics Market By Treatments, From 2016-2021 (USD Billion)
  44. France Leukemia Therapeutics Market By Drugs, From 2016-2021 (USD Billion)
Middle East And Africa Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail...
Latin America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Asia Pacific Clostridium Botulinum Market By Product (botulinum Toxin Type A And Botulinum Toxin Type B), By End User (aesthetic And Therapeutics), By Distribution Channel (hospitals, Clinics And Retail Pharmacies) ...
Europe Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And...
North America Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmaci...
Clostridium Botulinum Market By Product ( Botulinum Toxin Type A And Botulinum Toxin Type B), By End User ( Aesthetic And Therapeutics), By Distribution Channel ( Hospitals, Clinics And Retail Pharmacies) And By Reg...
The Dental Bone Graft Substitutes Market Is Predicted To Reach USD 664.3 Million With A CAGR Of 9.8% According To Market Data Forecast Report....
Middle East And Africa Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal D...
Latin America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...
Asia-Pacific Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Rege...
Europe Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Regenerati...
North America Dental Bone Graft Substitutes Market By Type ( Synthetic Bone Graft, Xenograft, Allograft And Demineralised Allograft) , By Application ( Socket Preservation, Ridge Augmentation, Periodontal Defect Reg...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.